UCB submits MAA, reports earnings

UCB Group (Euronext:UCB) disclosed in its 2Q10 financial results that it submitted an MAA in Europe for Xyrem sodium oxybate to treat fibromyalgia. The company expects a decision from the European Medicines Agency (EMA) in 1H11. UCB has ex-North American commercialization rights to the oral liquid formulation of sodium salt of gamma hydroxybutyrate (GHB) for fibromyalgia from Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ). Jazz markets Xyrem to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy.

UCB reported 1H10 revenues of EUR 1.64 billion, up 3% from EUR 1.6 billion in the same period last year. The company's six-month core EPS was EUR 1.17, up 21% from EUR 0.97 in 1H09. ...